Replies to post #309897 on Avid Bioservices Inc (CDMO)

[biopharm]

Dr Crystal L Mackall must be listening to Dr Jedd Wolchok

....
Her group was one of the first to demonstrate the success of a cancer therapy for pediatric acute lymphoblastic leukemia that works by modifying the patient’s own immune cells. The cells are removed from the patient, engineered to express cancer-specific receptors and returned to the patient, where they attack the cancer.

We have entered the golden age of immunotherapy for cancer.
Mackall also serves as co-leader of Stand Up 2 Cancer’s Pediatric Cancer Dream Team, a multi-institutional program focused on developing novel immunotherapies for childhood cancer. She holds patents or has patents pending for nine advances in cancer immune therapy.

“We have entered the golden age of immunotherapy for cancer,” Mackall said.
...
...
https://med.stanford.edu/news/all-news/2016/01/expert-in-cancer-immunotherapy-joins-stanford-medicine-faculty.html

Seems everyone has a sound bite for this IO age.....and I still like "The Enlightenment Age of Disease"

The USA
http://patents.justia.com/inventor/crystal-l-mackall

[biopharm]

T Cell Dysfunction, Cancer and Infection (A3)

Scientific Organizers: Daniel C. Douek, W. Nicholas Haining and Jedd D. Wolchok

January 16—20, 2018
Beaver Run Resort, Breckenridge, Colorado, USA

Sponsored by Incyte Corporation, Juno Therapeutics and TESARO, Inc.

...
...

Philip D. Greenberg, University of Washington, USA
Novel Approaches to Isolating Receptors and Engineering Cells to Target Tumor Antigens

...
...

Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center, USA
Clinical Results of Combined Checkpoint Blockades
...

https://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1545

Why is Dr Jedd Wolchok removed from this now ??? I highlighted in Red when Dr Jedd Wolchok was scheduled and appeared in the list and What clinical results of combined checkpoint blockades was this supposed to be talking about? My guess is PS Targeting was involved and now all of a sudden Dr Jedd Wolchok removed from this site ??

Investors should be sending in certified letters damnit now...ask if Dr Jedd Wolchok is on Peregrine BODs expert list to assess valuations of PS Targeting ....

This should open all eyes because I do not see Dr Jedd Wolchok as I copied and pasted from this site on the prior post posted above

T Cell Dysfunction, Cancer and Infection (A3)

Scientific Organizers: Daniel C. Douek, W. Nicholas Haining and Jedd D. Wolchok

January 16—20, 2018
Beaver Run Resort, Breckenridge, Colorado, USA

Sponsored by Incyte Corporation, Juno Therapeutics and TESARO, Inc.

...
...

Philip D. Greenberg, University of Washington, USA
Novel Approaches to Isolating Receptors and Engineering Cells to Target Tumor Antigens

...
...

Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center, USA
Clinical Results of Combined Checkpoint Blockades
...

https://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1545


Again, Dr Jedd Wolchok was in this list most recently and now removed....what the hell is going on??? !!!!!

17:00—19:00

Adoptive T Cell Transfer for Infection
Registered attendees can view abstracts starting on 12/16/2017

Colorado Ballroom
* Crystal L. Mackall, Stanford University, USA

Philip D. Greenberg, University of Washington, USA
Novel Approaches to Isolating Receptors and Engineering Cells to Target Tumor Antigens

James L. Riley, University of Pennsylvania, USA
Engineering T Cells to Functionally Cure HIV-1 Infection

Catherine M. Bollard, Children’s National Health System, USA
Virus-Specific T Cells Post HSCT- Broadening Applicability

Sanjivan Sanjivan Gautam, NCI, National Institutes of Health, USA
Short Talk: The Transcription Factor Myb Enhances CD8+ T Cell Memory and Anti-Tumor Function by Inducing Tcf7 and Restraining Zeb2 Transcription

19:00—20:00 Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00 Poster Session 2